<DOC>
	<DOCNO>NCT02904369</DOCNO>
	<brief_summary>This multi-center Phase I study design characterize PK PD F/TAF oral tablet assess systemic genital tract bioavailability healthy woman . The oral tablet use study F/TAF ( 200/10 mg ) , F/TAF ( 200/25 mg ) F/TDF ( 200/300 mg , Truvada ) . Samples obtain , dose two study phase .</brief_summary>
	<brief_title>PK PD Study Oral F/TAF HIV Prevention</brief_title>
	<detailed_description>The purpose multi-center Phase I protocol , title Exploratory Pharmacokinetic Pharmacodynamic Study Oral F/TAF Prevention HIV Acquisition assess local systemic pharmacokinetics ( PK ) , pharmacodynamics ( PD ) , safety characteristic three oral tablet : F/TAF ( 200/10 mg ) , F/TAF ( 200/25 mg ) F/TDF ( 200/300 mg ) . The study enroll healthy , non-pregnant , HIV negative , premenopausal woman ( age 18-50 ) risk pregnancy two phase : Single Dose phase ( one site ) Multiple Dose phase ( three site ) . The enrollment goal approximately 72 participant complete study . All 72 woman expect undergo Multiple Dose phase 24 woman expect complete study EVMS site also expect undergo Single Dose phase . In Single Dose phase , approximately 24 woman randomize one two product : F/TAF ( 200/25 mg ) F/TDF ( 200/300 mg ) , undergo blood , cervicovaginal ( CV ) , rectal sample collection single dose PK PD assessment . In Multiple Dose phase , approximately 72 woman randomize one three product : F/TAF ( 200/10 mg ) , F/TAF ( 200/25 mg ) F/TDF ( 200/300 mg ) , undergo blood , CV , rectal sample collection PK PD assessment , two week daily dose .</detailed_description>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<criteria>Age 18 50 year , inclusive General good health ( volunteer history per investigator judgment ) without clinically significant systemic disease ( include , limited significant liver disease/hepatitis , gastrointestinal disease , kidney disease , thyroid disease , osteoporosis bone disease , diabetes ) intact gastrointestinal tract , uterus cervix . History regular menstrual cycle ( cycle woman ) , volunteer report Estimated calculated creatinine clearance ( eCcr ) least 80 mL/min Body Mass Index ( BMI ) ≥18 &lt; 35kg/m2 ; total body weight &gt; 45 kg ( 99.2 lb ) History Pap smear followup consistent standard clinical practice outline Study Manual willing undergo Pap smear Visit 1 Willing give voluntary consent sign inform consent form Willing able comply protocol requirement , include swallow tablet May use progestinonly hormonal contraception must protect pregnancy : Condoms Combined hormonal contraceptive ( acceptable , recruitment effort make limit much possible number woman use study , represent majority participant . ) Copper IUD Sterilization either partner Heterosexual abstinence Same sex relationship If relationship , must mutually monogamous relationship partner know HIV positive know risk sexually transmit infection ( STIs ) Currently pregnant Currently breastfeed plan breastfeed course study History sensitivity/allergy component study product , topical anesthetic , silver nitrate Monsel 's solution In last three month , diagnose treat STI Positive test Trichomonas vaginalis , Neisseria gonorrhea , Chlamydia trachomatis , HIV , Hepatitis B surface antigen ( HBsAg ) Symptomatic bacterial vaginosis ( BV ) Current , active Hepatitis C infection Chronic acute vulvar vaginal symptom ( pain , irritation , spotting/bleeding , discharge , etc . ) Known bleed disorder could lead prolonged continuous bleed biopsy Systemic use last two week anticipate use study follow : corticosteroid , antibiotic , anticoagulant drug know prolong bleed and/or clotting , antifungal , antiviral antiretrovirals ( e.g . acyclovir , valacyclovir , Viread® , Atripla® , Emtriva® , Complera® ) , drug may interact TAF ( e.g. , protease inhibitor , anticonvulsant , antimycobacterials , St. John 's Wort ) . See Table 1 Patient Information brochure : Current anticipate chronic use NSAIDs Tylenol duration study Positive urine drug screen , know current drug alcohol abuse could impact study compliance . Note : therapeutic use benzodiazepine acceptable ; investigator may discuss CONRAD participant may eligible enrollment despite positive drug screen ( e.g. , false positive , use cold medication ) . Participation investigational trial use drug/device within last 30 day plan participation investigational use drug/device trial study Grade 2 high laboratory abnormality , per 2014 update Division AIDS , National Institute Allergy Infectious Disease ( DAIDS ) Table Grading Severity Adverse Events , clinically significant laboratory abnormality determine clinician Abnormal find laboratory physical examination social medical condition volunteer , opinion investigator , would make participation study unsafe would complicate interpretation data</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>